BSXBoston Scientific
$42.98-0.28%Real quote · delayedCardiovascular devicesMedtech & life sciences · 10 peers →🏛️ Company factsSEC filings + FINRA official data
Annual revenue $20.1B · latest quarter up 7.5% YoY · short activity below its recent average — bears covering.
FY revenue
$20.1B
2025-12
Latest Q YoY
+7.5%
Gross margin
69%
Diluted EPS
$1.96
Short volume
19.2%
20d avg 46.5% · shorts covering
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-08-06passive (13G)FMR LLC
- 2026-04-29passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-26passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability High · 80/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$0.86 vs $0.83+3.61%
- Mar 2026$0.80 vs $0.800%
- Dec 2025$0.80 vs $0.78+2.56%
- Sep 2025$0.75 vs $0.71+5.63%
The takeaway
This company habitually beats by +3% — the next report has to clear that bar to count as good news.
Analyst estimates, not our forecast · not investment advice
What's moving this stock lately
No recent news affecting this stock
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
4 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →